Cargando…

Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes

Metabolic mechanisms underlying the heterogeneity of major adverse cardiovascular (CV) event (MACE) risk in individuals with type 2 diabetes mellitus (T2D) remain unclear. We hypothesized that circulating metabolites reflecting mitochondrial dysfunction predict incident MACE in T2D. Targeted mass-sp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Regan, Jessica A., Mentz, Robert J., Nguyen, Maggie, Green, Jennifer B., Truby, Lauren K., Ilkayeva, Olga, Newgard, Christopher B., Buse, John B., Sourij, Harald, Sjöström, C. David, Sattar, Naveed, McGarrah, Robert W., Zheng, Yinggan, McGuire, Darren K., Standl, Eberhard, Armstrong, Paul, Peterson, Eric D., Hernandez, Adrian F., Holman, Rury R., Shah, Svati H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544215/ https://www.ncbi.nlm.nih.gov/pubmed/37552540 http://dx.doi.org/10.1172/jci.insight.168563

Ejemplares similares

Circulating long chain acylcarnitines and outcomes in diabetic heart failure: an HF-ACTION clinical trial substudy
por: Truby, Lauren K., et al.
Publicado: (2021)

Insulin action, type 2 diabetes, and branched-chain amino acids: A two-way street
por: White, Phillip J., et al.
Publicado: (2021)

Plasma metabolites associated with functional and clinical outcomes in heart failure with reduced ejection fraction with and without type 2 diabetes
por: Lerman, Joseph B., et al.
Publicado: (2022)

Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
por: Davis, Timothy M. E., et al.
Publicado: (2022)

Development and validation of a model to predict cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease
por: Stevens, Susanna R., et al.
Publicado: (2022)

Protein biomarkers of cardiac remodeling and inflammation associated with HFpEF and incident events
por: Regan, Jessica A., et al.
Publicado: (2022)

If You’re Ready, I Am Ready (But the Wait Is Harming Us Both) Individual Risks in Institutional Conversions
por: Sharp, Mindy McGarrah
Publicado: (2020)

Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure
por: Hunter, Wynn G., et al.
Publicado: (2016)

Pedagogies of Possibilities: Liberating Moral Imagination by Practicing Pastoral Aesthetics
por: Sharp, Melinda A. McGarrah
Publicado: (2021)

Altered branched-chain α-keto acid metabolism is a feature of NAFLD in individuals with severe obesity
por: Grenier-Larouche, Thomas, et al.
Publicado: (2022)

Branched-chain amino acid restriction in Zucker-fatty rats improves muscle insulin sensitivity by enhancing efficiency of fatty acid oxidation and acyl-glycine export
por: White, Phillip J., et al.
Publicado: (2016)

Novel plasma biomarkers improve discrimination of metabolic health independent of weight
por: Ellison, Stephen, et al.
Publicado: (2020)

Lipoprotein Subclasses Associated With High‐Risk Coronary Atherosclerotic Plaque: Insights From the PROMISE Clinical Trial
por: McGarrah, Robert W., et al.
Publicado: (2022)

Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial
por: Clegg, Lindsay E., et al.
Publicado: (2019)

Plasma acylcarnitines are associated with pulmonary hypertension
por: Luo, Nancy, et al.
Publicado: (2017)

Effect of once‐weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial
por: van der Aart‐van der Beek, Annemarie B., et al.
Publicado: (2020)

2,6-Anhydro-1,3-di-O-benzyl-d-mannitol
por: de Siqueira, Edmilson Clarindo, et al.
Publicado: (2011)

Dimethyl hydrazine-1,2-dicarboxylate–triphenylphosphine oxide (1/1)
por: Doboszewski, Bogdan, et al.
Publicado: (2011)

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
por: Nathan, David M., et al.
Publicado: (2009)

Patient preference for second and third line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study
por: Shields, Beverley M, et al.
Publicado: (2023)

Branched-chain α-ketoacids are preferentially reaminated and activate protein synthesis in the heart
por: Walejko, Jacquelyn M., et al.
Publicado: (2021)

Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction
por: Salah, Husam M., et al.
Publicado: (2021)

Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study
por: Donnelly, Louise A., et al.
Publicado: (2020)

Confirmation of Statin and Fibrate Use from Small-Volume Archived Plasma Samples by High-Throughput LC-MS/MS Method
por: Kusovschi, Jennifer D., et al.
Publicado: (2023)

Serum Metabolites Are Associated With HFpEF in Biopsy‐Proven Nonalcoholic Fatty Liver Disease
por: Wegermann, Kara, et al.
Publicado: (2023)

Metabolomics Applied to Diabetes Research: Moving From Information to Knowledge
por: Bain, James R., et al.
Publicado: (2009)

Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation
por: McGovern, Andrew P, et al.
Publicado: (2020)

Metabolites and diabetes remission after weight loss
por: Kwee, Lydia Coulter, et al.
Publicado: (2021)

Risk factors for cardiovascular disease among individuals with hepatic steatosis
por: Karády, Julia, et al.
Publicado: (2022)

Metabolic flexibility via mitochondrial BCAA carrier SLC25A44 is required for optimal fever
por: Yoneshiro, Takeshi, et al.
Publicado: (2021)

Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
por: Preiss, David, et al.
Publicado: (2012)

TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea—a MASTERMIND study protocol
por: Angwin, Catherine, et al.
Publicado: (2020)

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
por: Sattar, Naveed, et al.
Publicado: (2022)

Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS
por: Nauck, Michael A., et al.
Publicado: (2019)

Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010–2017
por: Dennis, John M., et al.
Publicado: (2019)

Remodeling of the Acetylproteome by SIRT3 Manipulation Fails to Affect Insulin Secretion or β Cell Metabolism in the Absence of Overnutrition
por: Peterson, Brett S., et al.
Publicado: (2018)

Effects of Epeleuton, a Novel Synthetic Second‐Generation n‐3 Fatty Acid, on Non‐Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers
por: Climax, John, et al.
Publicado: (2020)

BMI, RQ, Diabetes, and Sex Affect the Relationships Between Amino Acids and Clamp Measures of Insulin Action in Humans
por: Thalacker-Mercer, Anna E., et al.
Publicado: (2014)

Evaluation of a Self-Administered Oral Glucose Tolerance Test
por: Bethel, M. Angelyn, et al.
Publicado: (2013)

Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease
por: Bethel, M. Angelyn, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sir9kouk2j4lrq9gn6mkmnaf5m